Scholars@Duke
Jonathan Huggins

Jonathan Huggins

Assistant Professor of Medicine
Medicine, Infectious Diseases

Scholarly Works

Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.

Journal article Transplant Cell Ther · May 2026 Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). While life-threatening toxicities like cytokine release syndrome and immune effector c ... Full text Link to item Cite

Respiratory Viral Infections Following CD19 CAR T-Cell Therapy.

Journal article J Med Virol · May 2026 Respiratory viral infections (RVI) are an important infectious complication after chimeric antigen receptor (CAR) T-cell therapy. However, the epidemiology of RVI following CAR T-cell therapy and their risk factors are not well defined. To describe the inc ... Full text Link to item Cite

Organ-specific differences in the epidemiology of cytomegalovirus infections in high-risk (cytomegalovirus donor seropositive, recipient seronegative) solid organ transplant recipients with prolonged follow-up: A 10-year experience.

Journal article Am J Transplant · March 26, 2026 Cytomegalovirus (CMV) causes significant morbidity in CMV donor seropositive/recipient seronegative (D+R-) solid organ transplant recipients, but organ-specific differences in CMV epidemiology and the utility of laboratory surveillance after prophylaxis (S ... Full text Link to item Cite

Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.

Journal article Open Forum Infect Dis · September 2025 Infections are increasingly recognized as a complication of chimeric antigen receptor T-cell (CAR-T) therapy however the incidence of infections after non-CD19 targeted CAR-T is not yet known. We report, for the first time, infectious complications after C ... Full text Open Access Link to item Cite

Invasive surgical site infections after lung transplantation: contemporary risk factors and associated clinical outcomes.

Journal article JHLT Open · August 2025 BACKGROUND: Invasive primary surgical site infections (IP-SSI) complicate lung transplant (LT) surgery. Identification of IP-SSI risk factors is critical to IP-SSI prevention. METHODS: This single-center retrospective cohort study of adult patients who und ... Full text Open Access Link to item Cite

West Nile Virus Encephalitis in a Lung Transplant Recipient

Conference JOURNAL OF HEART AND LUNG TRANSPLANTATION · April 2025 Link to item Cite

Incidence of infection in patients with acute myeloid leukemia receiving high-dose cytarabine consolidation.

Journal article Ann Hematol · December 2024 Infection risk during high-dose cytarabine (HiDAC) consolidation following induction therapy for acute myeloid leukemia (AML) is not well understood complicating decisions regarding antimicrobial prophylaxis during this period. We performed a retrospective ... Full text Link to item Cite

Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Conference Blood · November 5, 2024 Introduction: Chimeric antigen receptor-T (CAR-T) cell therapy has revolutionized the treatment landscape in multiple myeloma (MM). Treatment with commercial CAR-T cells targeting B-cell ... Full text Cite

Infectious Complications Following CD30 Chimeric Antigen Receptor T-Cell Therapy in Adults.

Journal article medRxiv · July 11, 2024 UNLABELLED: Infections are increasingly recognized as a common complication of chimeric antigen receptor (CAR) T-cell therapy. The incidence of clinically-defined infection after CD19.CAR T-cell therapy for relapsed/refractory lymphoma ranges from 60-90% i ... Full text Link to item Cite

Risk Factors for Invasive Fungal Infection in Lung Transplant Recipients on Universal Antifungal Prophylaxis.

Journal article Open Forum Infect Dis · February 2024 BACKGROUND: Many centers use universal antifungal prophylaxis after lung transplant, but risk factors for invasive fungal infection (IFI) in this setting are poorly described. METHODS: This retrospective, single-center cohort study including 603 lung trans ... Full text Open Access Link to item Cite

Effects of antimicrobial therapy duration and class on risk of antimicrobial-resistant Gram-negative bacillus bloodstream infection in patients with AML.

Journal article Transpl Infect Dis · December 2023 BACKGROUND: Antimicrobial-resistant Gram-negative bacilli (ARGNB) bloodstream infection (BSI) has been associated with prior antibiotic exposure among hematologic malignancy patients. The relationships between days of therapy (DOT), antimicrobial class, an ... Full text Link to item Cite

Safety of Inhaled Amphotericin B Lipid Complex as Antifungal Prophylaxis in Lung Transplant Recipients.

Journal article Antimicrob Agents Chemother · June 21, 2022 Inhaled formulations of amphotericin B are the most widely used antifungal prophylactic agents in lung transplant recipients, yet there are limited data on their safety. We performed a single-center retrospective cohort study of 603 consecutive patients wh ... Full text Link to item Cite

Candida Infective Endocarditis: A Retrospective Study of Patient Characteristics and Risk Factors for Death in 703 United States Cases, 2015-2019.

Journal article Open Forum Infect Dis · February 2021 BACKGROUND: Candida endocarditis is a rare, sometimes fatal complication of candidemia. Past investigations of this condition are limited by small sample sizes. We used the Vizient clinical database to report on characteristics of patients with Candida end ... Full text Link to item Cite